Friday, March 27, 2026 For Patients CME Credits Newsletters
Subscribe

Drug Pipeline

1 published article · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Children
A Phase 3 trial is assessing the safety and immunogenicity of the CHIKV VLP vaccine in children aged 1 to <12 years. Primary endpoints include the incidence of AESI, MAAEs, and SAEs, and the serorespo…
Researchers are studying a new vaccine for chikungunya virus in children. They want to see if it is safe and helps the body build protection against the virus.…
Phase III CT.gov n=720 8h ago Read →
CT.gov · Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Childr… CT.gov · Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients CT.gov · Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma CT.gov · Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD CT.gov · Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria CT.gov · Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary O…